Changing the future of Oncology.
Clinical/Scientific Presentation and Publication Highlights
Bristol Myers Squibb Investor Series
June 25, 2020 at 11:30am ET WEBCAST View This Presentation June 22, 2020 at 11:30am ET WEBCAST View This Presentation
M1231: A First In-Class Bispecific ADC Targeting EGFR and MUC1 Presented by EMD Serono at American Association for Cancer Research (AACR) Virtual Meeting II on June 24, 2020 – Presentation
AACR requires pre-registration to access this presentation. Oral Presentation & Discussion, timestamp 1:43:36, Only Available to Registrants , CLICK HERE
American Association for Cancer Research (AACR) 2020 Virtual Meeting II – Abstract
STRO-002, An Anti-FolRα ADC, Demonstrates Immune-Modulating Properties and Potentiates PD-L1 Blockade Millicent Embry*, Sihong Zhou*, Christine Cheng, Janice Yu, Cristina Abrahams, Xiaofan Li, Jeff Hanson, Cuong Tran, Gang Yin, Shamim Ahmad, Krishna Bajjuri, Venita...
American Association for Cancer Research (AACR) 2020 Virtual Meeting II – Poster
STRO-002, An Anti-FolRα ADC, Demonstrates Immune-Modulating Properties and Potentiates PD-L1 Blackade Please Click the Link, STRO-002 AACR 2020 Poster to Enlarge Please click link to view, Poster Script Please click play button below to listen, Poster Narrative
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif., June 22, 2020...
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif., June 9, 2020–...
Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
Dr. Wendel Naumann of The Levine Cancer Institute, Non-Audio Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020Download Non-Audio Presentation CLICK HERE
Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation
Download Presentation CLICK HERE
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer - 62% of patients saw a reduction in CA-125 levels of 50% or more or a normalization of CA-125 levels - 35% of patients who were evaluable for progression have...
American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 – STRO-002 Abstract
STRO-002-GM1, a first in human, phase 1 Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC), including Fallopian Tube or Primary Peritoneal...